MenQuadfi

MenQuadfi is a quadrivalent meningococcal conjugate vaccine designed to protect against invasive disease caused by Neisseria meningitidis serogroups A, C, W, and Y. It is produced by Sanofi Pasteur and is used to reduce the risk of meningococcal disease in individuals aged 2 years and older.

The vaccine is a protein-conjugate formulation. The polysaccharide capsules of the four meningococcal serogroups are covalently linked to a carrier protein, typically a tetanus toxoid, to create a T-cell dependent immune response. This conjugation enhances the body’s ability to develop long-lasting immunity, including in younger recipients.

Indications and usage vary by region, but MenQuadfi is generally indicated for active immunization to prevent invasive meningococcal disease caused by serogroups A, C, W, and Y. It is employed in routine vaccination programs for adolescents and other at-risk populations, as well as for travelers or outbreak control in some settings. The standard primary dose is administered intramuscularly as a 0.5 mL injection. In many health systems a single primary dose is used, with booster doses recommended according to age and risk factors per local guidelines.

Safety considerations include common reactions such as pain at the injection site, redness, swelling, fever, and irritability. Severe adverse events are rare. Contraindications typically include a known severe allergic reaction to a previous dose or to any component of the vaccine, as well as precaution for individuals with certain acute illnesses. As with all vaccines, vaccination decisions should align with national immunization guidelines and local public health recommendations.

See also: meningococcal disease, MenACWY vaccines, Sanofi Pasteur.